At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in personalized treatment of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations.

Latest news

January 7, 2016

World’s first clinical trial for anti-Abeta vaccine targeting Alzheimer’s disease-like characteristics in people with Down syndrome

September 23, 2015

AC Immune signs collaboration agreement with Nestlé Institute of Health Sciences to develop Alzheimer’s disease diagnostic

July 22, 2015

AC Immune receives milestone payment for crenezumab moving into phase III clinical development in Alzheimer’s disease

Company information

Discover more about us, who we are, and how we innovate to improve neurodegenerative disease understanding and develop breakthrough therapies.

Product pipeline

One of the world’s largest Alzheimer’s product pipelines with complementary diagnostic agents driven by proprietary technology platforms.